Although they have already shown safety through aGVHD and that logic would also mean they had seen the interim results of the ARDS P3 before getting the MIS-C trial go ahead. My feel is that they had MIS-C on their radar and knew that the FDA are well aware of Ryoncil's safety profile for pediatrics and put in the application as soon as they were able.
Following on from your mum's thoughts, Ryoncil has great advantage in this area for it's excellent pediatric safety profile. Some of the non-contenders may have issues in regards to adverse reactions etc. or just do not have the proven safety profile for a P3.
Just my 2 cents
Coming News ???, page-203
-
- There are more pages in this discussion • 308 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |